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EDITORIAL COMMENT
High-Fat Diets and
Cardiovascular Disease
Are Nutritional Supplements Useful?*
Jane E. Freedman, MD, FACC
Boston, Massachusetts
Over the past two decades, significant progress has been
made in the treatment of acute and chronic cardiovascular
disease. Although a large part of this success has been
attributable to medical and technical advances, patient
education concerning the importance of cardiovascular risk
factors has been pivotal. Control of risk factors such as
hypertension, smoking, and hypercholesterolemia has been
successful because of patient education and medication
development. Tempering some of these successes, however,
is the growing epidemic of obesity in the U.S. According to
the National Center for Health Statistics (1999), 61% of
adults in the U.S. are overweight (body mass index [BMI]
25 to 29.9 kg/m2), and 26% are obese (BMI 30 kg/m2).
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Elevated BMI, particularly caused by abdominal or upper-
body obesity, has been associated with diseases and meta-
bolic abnormalities including hyperinsulinemia, insulin re-
sistance, type 2 diabetes, hypertension, dyslipidemia, and
coronary heart disease. Unfortunately, obesity has also
become a growing problem in children and adolescents,
with the prevalence of overweight children increasing from
5% to 11% over the past 30 years (1). Whereas useful
medications have been developed to treat hypercholesterol-
emia, no such therapies are available to counteract the
detrimental effects of saturated fats or high caloric intake on
cardiovascular disease.
Dietary intake of specific nutrients has been suggested as
a means of modifying the progression of cardiovascular
disease. One such example is the proposed use of foods rich
in select vitamins or flavonoids. Epidemiologic studies have
reported an inverse relationship between the total dietary
intake of plant flavonoids and the incidence of a cardiovas-
cular disease (2,3). It has also been suggested that red wine
consumption may reduce coronary disease (4,5). The source
of this beneficial effect is believed to be flavonoids, poly-
phenol derivatives of diphenylpyrans that are found in plant
but not animal food products. The skins, seeds, and stems
from purple grapes are rich sources of these flavonoids.
However, large, prospective trials evaluating diets rich in
flavonoids are lacking and, at this time, benefit can only be
inferred. Similarly, observational epidemiologic studies have
associated intake of antioxidant vitamins with lower cardio-
vascular disease risk. Although increased endogenous anti-
oxidant levels are associated with encouraging outcomes (6),
recent studies have failed to demonstrate cardiovascular
benefit from vitamin supplementation (7,8).
A proposed mechanism for the beneficial cardiovascular
effects of flavonoids and vitamins is enhanced bioactivity of
nitric oxide (NO), a potent vasodilator and platelet inhibi-
tor. As most acute and chronic coronary syndromes are
caused by attenuated vascular reactivity associated with
platelet adhesion, aggregation, and thrombus formation in
areas of ruptured atheromatous plaque (9,10), it has been
suggested that select flavonoids may inhibit thrombosis and
enhance vasodilation by a NO-dependent process (11–13).
Reported mechanisms for the flavonoid- or vitamin-
dependent increase in NO have included metabolism of
reactive oxygen species, as well as regulation of endothelial
NO synthase transcriptional or signaling pathways (14).
The role of the vascular endothelium, which mediates
vasomotor tone through NO release, has been extensively
characterized. Various methods have been utilized to assess
the impact of therapeutic interventions on vascular tone.
Common tests used for evaluating endothelial function
include studies of flow-mediated coronary or brachial artery
dilation. It is well established that cardiovascular disease and
coronary risk factors including cholesterol level, male gen-
der, family history, and age, are associated with impaired
endothelium-dependent vasodilation in coronary arteries
(15). Various dietary and nutritional interventions have been
previously shown to alter coronary or peripheral vascular
reactivity. However, although studies of impaired coronary
vasoreactivity have been associated with increased clinical
events (16,17), outcome studies demonstrating the clinical
relevance of endothelial dysfunction in the brachial circula-
tion are still needed (18). In addition, therapies including
vitamin E (19) and estrogen (20) have been associated with
enhanced NO-dependent flow-mediated vascular relaxation
but have failed to demonstrate cardiovascular benefit in
long-term prospective trials (8).
In the current issue of the Journal, Plotnick et al. (21)
examine the effect of nutritional supplements on flow-
mediated brachial artery vasoactivity after a high-fat meal.
In this study, healthy subjects were randomized to four
weeks of daily supplementation with a powdered fruit
vegetable juice, a powdered juice and herbal/antioxidant
supplement, or placebo. The subjects then consumed a
high-calorie, high-fat meal containing 14 g of saturated fat
and devoid of any fruits or vegetables, and flow-mediated
brachial artery reactivity was measured. An important find-
ing of this study was that the nutrient supplement did not
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need to be consumed with the high-fat meal, although how
long the changes in flow-mediated reactivity persisted was
not evaluated.
The first supplement utilized in this study contained a
combination of a multiple fruit and vegetable concentrates.
Because of this mix of concentrates, it is unclear if these
findings would be similar using other related nutrient
preparations or foods. Because the active components of this
supplement were not identified, and the compounds were
not monitored either directly or utilizing surrogate biomar-
kers, it cannot be assumed that subsequent preparations of
this or similar supplements will retain their vasoactive
properties. Also, because the herbal extract was not tested
alone, it is impossible to know if it has any beneficial effects
when used in isolation. The only conclusion that can be
drawn is that this extract did not lead to any significant
additive effects when given with the juice concentrate
powder. Whereas the fruit and vegetable concentrate ap-
peared to be of benefit, the addition of the vitamin supple-
ment appeared to have no additional effect on brachial
function and led to an increase in total and low-density
lipoprotein cholesterol as compared with the juice concen-
trate alone. Interestingly, a recent large prospective trial
suggested that vitamin supplements negated the atheroscle-
rotic attenuating effects of lipid-lowering drugs (22). In this
study, treatment with antioxidants alone lowered the high-
density lipoprotein (HDL)2 level, and antioxidant therapy
blunted the rise in HDL2 seen with the lipid-altering
treatment.
The mechanism for the finding of enhanced brachial
reactivity after phytonutritional supplementation is not
known. Although the authors demonstrate increased plasma
levels of nitrate/nitrite, this does not provide enough infor-
mation to determine whether the increase in NO is due to
enhanced vascular release or increased bioavailability. Sev-
eral findings argue against the plasma nitrate/nitrite levels as
reflecting the total body NO production. These include the
lack of correlation between plasma nitrate/nitrite levels and
change in NO-dependent vasodilation. Also, arginine was
present in the vitamin/antioxidant supplement and did not
alter the nitrate/nitrite levels. Although plasma nitrate/
nitrite content changed with supplementation, these levels
depend upon diet and, as discussed in the study, dietary
protein was not regulated, making these levels unreliable.
Further complicating this measurement is the nitrite report-
edly contained in the juice extract. Because of these limita-
tions, it cannot be assumed that total NO or NO synthase
activity increased in the subjects on the supplements. Al-
though the vascular changes may be due to a direct
antioxidant effect, this cannot be definitely concluded as
other reactive oxygen species or antioxidants were not
measured. In addition, many vitamins and phytonutrients
have been shown to have nonantioxidant mechanisms for
altering vascular function, including effects on signaling
pathways (14). Alpha-tocopherol, as well as purple grape
juice and other flavonoids, have been shown to influence
vascular NO by a protein kinase C (PKC)-dependent
mechanism (23,24). Reactive oxygen species may also cause
activation through regulation of PKC (25); therefore, anti-
oxidant metabolism of reactive oxygen species by phytonu-
trients may influence signaling activity and, potentially,
vascular NO release.
In summary, the study by Plotnick et al. (21) presents
intriguing data concerning a potential mechanism for the
beneficial effects of flavonoid supplementation and adds to
the growing information available demonstrating that sub-
stances rich in flavonoids enhance brachial function. Al-
though these findings are notable, they are not broadly
clinically relevant until tested prospectively with longer-
term clinical end points. Thus, the current findings should
not lead to the general recommendation of phytonutrients
for the modification of cardiovascular disease; nor should
these findings suggest that the clearly established diseases
associated with high-fat or high-calorie diets can be offset
by the use of nutritional supplements. Although these
findings beckon us to draw broader implications, even if
proven true in larger studies, it is doubtful that this will lead
to a recommendation of high-calorie, high-fat diets. Per-
haps these findings could be interpreted in a more limited
manner—i.e., does the intake of a fatty meal lead to
detrimental vascular effects that can be acutely treated? If
validated in subjects with cardiovascular disease, would such
studies lead to the use of nutritional supplementation with
the occasional high-fat meal or should we just be recom-
mending a salad with the steak dinner?
Thus, this study does not suggest that a phytonutrient or
vitamin supplement is the solution for high-fat, low-fiber,
low-nutrient diets but instead reinforces the positive effects
of nutrient-rich fruits and vegetables. Validation of the
potentially broader implication of these results, namely that
intake of specific fresh fruits and vegetables is beneficial to
cardiovascular health and can balance the potentially detri-
mental effects of the fat intake in our diet, would be of
significant interest.
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